158 related articles for article (PubMed ID: 35757870)
1. The continuum of care of anticancer treatment-induced hypothyroidism in patients with solid non-thyroid tumors: time for an intimate collaboration between oncologists and endocrinologists.
Deligiorgi MV; Trafalis DT
Expert Rev Clin Pharmacol; 2022 May; 15(5):531-549. PubMed ID: 35757870
[TBL] [Abstract][Full Text] [Related]
2. The Clinical Relevance of Hypothyroidism in Patients with Solid Non-Thyroid Cancer: A Tantalizing Conundrum.
Deligiorgi MV; Trafalis DT
J Clin Med; 2022 Jun; 11(12):. PubMed ID: 35743483
[TBL] [Abstract][Full Text] [Related]
3. Thyroid dysfunction as an unintended side effect of anticancer drugs.
Torino F; Barnabei A; Paragliola R; Baldelli R; Appetecchia M; Corsello SM
Thyroid; 2013 Nov; 23(11):1345-66. PubMed ID: 23750887
[TBL] [Abstract][Full Text] [Related]
4. AN ITALIAN SURVEY OF COMPLIANCE WITH MAJOR GUIDELINES FOR L-THYROXINE OF PRIMARY HYPOTHYROIDISM.
Vezzani S; Giannetta E; Altieri B; Barbonetti A; Bellastella G; Certo R; Cignarelli A; Cinti F; D'Andrea S; Di Dalmazi G; Frara S; Garelli S; Giuffrida G; Maiorino MI; Mele C; Mezza T; Pani MG; Samà MT; Satta C; Santi D
Endocr Pract; 2018 May; 24(5):419-428. PubMed ID: 29847168
[TBL] [Abstract][Full Text] [Related]
5. Refining personalized diagnosis, treatment and exploitation of hypothyroidism related to solid nonthyroid cancer.
Deligiorgi MV; Trafalis DT
Per Med; 2023 Jan; 20(1):87-105. PubMed ID: 36454100
[TBL] [Abstract][Full Text] [Related]
6. ITALIAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS STATEMENT-REPLACEMENT THERAPY FOR PRIMARY HYPOTHYROIDISM: A BRIEF GUIDE FOR CLINICAL PRACTICE.
Guglielmi R; Frasoldati A; Zini M; Grimaldi F; Gharib H; Garber JR; Papini E
Endocr Pract; 2016 Nov; 22(11):1319-1326. PubMed ID: 27482609
[TBL] [Abstract][Full Text] [Related]
7. The Continuum of Thyroid Disorders Related to Immune Checkpoint Inhibitors: Still Many Pending Queries.
Deligiorgi MV; Sagredou S; Vakkas L; Trafalis DT
Cancers (Basel); 2021 Oct; 13(21):. PubMed ID: 34771441
[TBL] [Abstract][Full Text] [Related]
8. Thyroid dysfunction from antineoplastic agents.
Hamnvik OP; Larsen PR; Marqusee E
J Natl Cancer Inst; 2011 Nov; 103(21):1572-87. PubMed ID: 22010182
[TBL] [Abstract][Full Text] [Related]
9. Thyroxine replacement: a clinical endocrinologist's viewpoint.
Eligar V; Taylor PN; Okosieme OE; Leese GP; Dayan CM
Ann Clin Biochem; 2016 Jul; 53(Pt 4):421-33. PubMed ID: 27126268
[TBL] [Abstract][Full Text] [Related]
10. Thyroid disorders associated with immune control point inhibitors.
Fidilio E; Navarro-González E; Romero-Lluch AR; Iglesias P; Diez Gómez JJ; Anda Apiñániz E; Santos Mazo E; Zafón C
Endocrinol Diabetes Nutr (Engl Ed); 2021; 68(6):408-415. PubMed ID: 34742474
[TBL] [Abstract][Full Text] [Related]
11. Clinical practice guidelines for hypothyroidism in adults: cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association.
Garber JR; Cobin RH; Gharib H; Hennessey JV; Klein I; Mechanick JI; Pessah-Pollack R; Singer PA; Woeber KA;
Thyroid; 2012 Dec; 22(12):1200-35. PubMed ID: 22954017
[TBL] [Abstract][Full Text] [Related]
12. Anticancer Drug-induced Thyroid Dysfunction.
Bhattacharya S; Goyal A; Kaur P; Singh R; Kalra S
Eur Endocrinol; 2020 Apr; 16(1):32-39. PubMed ID: 32595767
[TBL] [Abstract][Full Text] [Related]
13. The emergence of levothyroxine as a treatment for hypothyroidism.
Hennessey JV
Endocrine; 2017 Jan; 55(1):6-18. PubMed ID: 27981511
[TBL] [Abstract][Full Text] [Related]
14. Thyroid dysfunction and tyrosine kinase inhibitors in renal cell carcinoma.
Bianchi L; Rossi L; Tomao F; Papa A; Zoratto F; Tomao S
Endocr Relat Cancer; 2013 Oct; 20(5):R233-45. PubMed ID: 23833016
[TBL] [Abstract][Full Text] [Related]
15. Hypothyroidism During Tyrosine Kinase Inhibitor Therapy Is Associated with Longer Survival in Patients with Advanced Nonthyroidal Cancers.
Lechner MG; Vyas CM; Hamnvik OR; Alexander EK; Larsen PR; Choueiri TK; Angell TE
Thyroid; 2018 Apr; 28(4):445-453. PubMed ID: 29652597
[TBL] [Abstract][Full Text] [Related]
16. Endocrine toxicity of immune checkpoint inhibitors: essential crosstalk between endocrinologists and oncologists.
Illouz F; Briet C; Cloix L; Le Corre Y; Baize N; Urban T; Martin L; Rodien P
Cancer Med; 2017 Aug; 6(8):1923-1929. PubMed ID: 28719055
[TBL] [Abstract][Full Text] [Related]
17. Expert opinion on thyroid complications of new anti-cancer therapies: Tyrosine kinase inhibitors.
Drui D; Illouz F; Do Cao C; Caron P
Ann Endocrinol (Paris); 2018 Oct; 79(5):569-573. PubMed ID: 30126626
[TBL] [Abstract][Full Text] [Related]
18. [Endocrine complications of modern cancer therapy].
Čáp J
Vnitr Lek; 2016; 62(9 Suppl 3):45-49. PubMed ID: 27734691
[TBL] [Abstract][Full Text] [Related]
19. Clinical, behavioural and pharmacogenomic factors influencing the response to levothyroxine therapy in patients with primary hypothyroidism-protocol for a systematic review.
Dew R; Okosieme O; Dayan C; Eligar V; Khan I; Razvi S; Pearce S; Wilkes S
Syst Rev; 2017 Mar; 6(1):60. PubMed ID: 28327186
[TBL] [Abstract][Full Text] [Related]
20. Clinical practice guidelines for hypothyroidism in adults: cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association.
Garber JR; Cobin RH; Gharib H; Hennessey JV; Klein I; Mechanick JI; Pessah-Pollack R; Singer PA; Woeber KA;
Endocr Pract; 2012; 18(6):988-1028. PubMed ID: 23246686
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
